Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine - Top-Institutions - MDSpire

Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine

  • By

  • Caroline M Kopruszinski

  • John E Linley

  • Peter Thornton

  • Alison S Walker

  • Philip Newton

  • Sadhana Podichetty

  • Radhey Hemendra Ruparel

  • Luiz Henrique Moreira de Souza

  • Edita Navratilova

  • Guy Meno-Tetang

  • Ian Gurrell

  • David W Dodick

  • Claire Dobson

  • Tharani Chessell

  • Frank Porreca

  • Iain Chessell

  • February 28, 2025

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Headache Medicine
    • Translational Neuroscience

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Pain Medicine
    • Neuropharmacology

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Neurology
    • Headache Medicine
    • Clinical Neuroscience

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Pain Research
    • Translational Medicine

  • #5

    University of Pennsylvania
    University of Pennsylvania

    Philadelphia, PA

    Key Differentiators

    • Neurology
    • Headache Medicine
    • Neuropharmacology

Original Source(s)

Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine

  • by Caroline M Kopruszinski, John E Linley, Peter Thornton, Alison S Walker, Philip Newton, Sadhana Podichetty, Radhey Hemendra Ruparel, Luiz Henrique Moreira de Souza, Edita Navratilova, Guy Meno-Tetang, Ian Gurrell, David W Dodick, Claire Dobson, Tharani Chessell, Frank Porreca, Iain Chessell

  • February 28, 2025

Related Content

Migraine, comorbidity, and risks of severe maternal and neonatal morbidity or mortality: a population-based cohort study

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Correction: Migrainous vertigo impairs adaptive learning as a function of uncertainty